When Enough Is Too Much: New Strategies to Treat Obesity by unknown
Chemistry & Biology, Vol. 11, 1025–1026, August, 2004, 2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j .chembiol .2004.08.005
Innovations
When Enough Is Too Much:
New Strategies to Treat Obesity
PYY3-36 levels rose correspond- a collection of nerve cells located in
the hypothalamus. If these receptorsingly with calorie intake. “Research-
are not blocked, nerve cells are acti-ers at Hammersmith Hospital in
US government organizations esti-
mate the US adult overweight and
obese population at 65%; 13% of
children. The Centers for Disease vated releasing neuropeptide NPY,London then did the reciprocal ex-
Control and Prevention now classify producing ongoing sensations ofperiment showing that if you infused
obesity as nearly equal to tobacco hunger. Quay explains that the ar-PYY3-36 into obese volunteers, they
use as the number one health threat cuate nucleus does not have awould eat significantly fewer calo-
for Americans. However, the choices blood-brain barrier, so the PYY3-36ries after taking PYY3-36 as com-
for prescription products aimed at peptide gets into the bloodstream,pared to placebo,” says Quay [1].
combating the new “obesity epi- diffuses to the arcuate nucleus, andSpecifically, they found that in both
demic” are limited to only two: Meri- binds tightly to the Y2 receptor withobese and lean people, PYY3-36 re-
dia (sibutramine) and Xenical (orlis- picomolar affinity within 35–60 minduced overall calorie intake by 30%
tat). Though the obesity market is of eating. “Then your brain says ‘I’m2 hr post-transfusion. They also dis-
certainly demanding medications, full and I don’t need to eat any-covered that endogenous levels of
few overweight or obese people more’,” says Quay. “But one of thePYY3-36 were low in obese volun-
maintain long-term therapy with ei- problems with obesity today has toteers, suggesting that PYY3-36 defi-
ther drug, largely because of side do with the very high-density dietsciency may contribute to obesity. In-
effects. This leaves the door open (with respect to calories) people areterestingly, other researchers have
for any company that can come up eating now. The problem is that if
with an effective and relatively side- you go to a fast-food restaurant you
effect-free solution. In pursuit of this can get two days of calories in 45
The Centers for Diseasegoal are two small companies lo- min, usually more quickly than the
PYY3-36 can tell you to stop eating.”cated on either coast of the US, both Control and Prevention
with naturally occurring compounds Nastech now seeks to match thenow classify obesity asgeared toward reducing overall cal- results of the infused PYY 3-36 stud-
nearlyequal to tobaccouseorie intake by producing feelings of ies using its own intranasal formula-
tion. To date, three phase I studiessatisfied hunger, or satiety, sooner as the number one health
rather than later. have been performed, the most re-threat for Americans.Nastech Pharmaceuticals cent reported in late June 2004. That
Nastech, a 20-year-old company week-long phase IC study among 37
based in Bothell, WA, has evolved obese people showed an average
very recently questioned some ofits focus toward novel drug delivery weight loss of 1.3 pounds in those
the earlier animal studies done withsolutions. “We’re trying to use mo- who sniffed one dose of PYY3-36
injected PYY3-36 by the Hammer-lecular biology tools to solve drug 1 hr before eating. That may not seem
smith group, claiming that calorie re-delivery problems,” says Steven impressive, but Quay asserts that “if
duction and weight loss could notQuay, MD, PhD, Nastech’s Presi- you talk to doctors who counsel
be replicated in test animals [2]. Butdent and CEO. “Currently, we are people on weight loss, 1 to 2 pounds
Quay is not fazed by the ongoingfocusing on intranasal delivery.” of true body weight loss per week is
publications controversy because ofNastech’s obesity therapy, PYY3- where you should be. More than that
the proven results of PYY3-36 in hu-36, a naturally occurring protein and you are losing water, which is a
man tests, including Nastech’s own.found in the gut, is a member of the transient thing.” Depending on the
“It is an interesting controversy, oneneuropeptide Y family known to be number of doses received, volun-
that would be more worrisome if weassociated with feelings of hunger teers reduced daily calorie intake
didn’t have human data that wasand satiety. “PYY is the peptide that from 77 to 648 calories.
positive, showing PYY3-36 reducesgives you the feeling of fullness,” He is also pleased with the phar-
calorie intake and has a substantialsays Quay. macodynamics of the intranasal for-
effect on scores of satiety,” he says.About 10 years ago, investigators mulation, which uses the same nasal
“You have to think of the brain asdiscovered that PYY3-36 appears in actuator found in at least 20 different
a computer room with no windows,”the bloodstream after oral food in- commercial nasal sprays, including
says Quay. “Everything we think ortake, typically within 35–60 min. Flonase for allergy. “In our human
experience is really a series of re-“One of the most impressive studies studies, we have gotten better bio-
ceptors being activated.” It is be-with PYY3-36 showed that its blood availability than we had predicted,
lieved that after a meal, PYY3-36concentration was strictly related to and we were able to get up to nine
produces satiety by occupying thethe number of calories being eaten,” times the dosage you usually get
after a big meal,” says Quay. “So wesays Quay. Researchers found that Y2 receptor in the arcuate nucleus,
Chemistry & Biology
1026
Thone-Reineke, C., Ortmann, S., Klaus,have a lot of dynamic range in terms means less of it is feeding back to
S., Hagan, M.M., Chandler, P.C., Oswald,of what we can deliver into the the brain. Then whatever appetite
K.D., Benoit, S.C., et al. (2004). Naturebloodstream. signals go out from the brain are in-
430, 1 p. following 165; discussion 2 p.
Looking forward, Nastech will adequate in obese people.” Re- following 165, and Batterham, R.L. et al.,
begin a phase II placebo-controlled searchers at Manhattan have evi- ibid, reply.
3. Alemany, M., Fernandez-Lopez, J.A., Pe-trial examining weight loss over a dence that giving exogenous OE
trobelli, A., Granada, M., Foz, M., and Re-six-month period. “This is planned reduces appetite, both in obese and
mesar, X. (2003). Med. Clin. (Barc.) 121,for later in 2004,” says Quay. normal-weighted animals. The plan
496–499.Manhattan Pharmaceuticals at Manhattan in the future is to try
to find out why OE levels fall in obeseManhattan Pharmaceuticals, based Chemistry & Biology invites your
in New York City, was founded in people, but their first priority is to comments on this topic. Please
August 2001 with one specific goal. investigate what happens when test write to the editors at chembiol@
“It was built specifically to develop subjects are given more. cell.com.
an improved obesity therapeutic,” “Aside from their side effects,
Alice A. McCarthy is a freelance sciencesays Leonard Firestone, MD, Man- drugs like Xenical and Meridia are
writer based in Gloucester, MA (alice@hattan’s President and CEO. In this only minimally effective: only 5%–
alicemccarthy.com).case, the therapy is oleoyl estrone 8% loss of body mass can be ex-
pected,” says Firestone. “Frankly,(OE), a naturally occurring fatty acid
ester of estrone first developed by we need something that helps you
lose 15%–20% of body mass and isresearchers at the University of Bar-
celona, including Dr. Maria Alemany, not riddled with side effects.” Man-
hattan’s researchers claim that inwell known for his research into the
study of calorie intake, appetite, and the laboratory OE has reduced calo-
ric intake between 40%–70%, andfat deposition regulation. “Dr. Alem-
any began to look for the true media- that translates over time into a 15%
body mass reduction. A single-per-tors of satiety in the blood and in
the process focused on the steroids son study from Barcelona published
in October 2003 found that OE re-coming up with the esterified ste-
roids, particularly the fatty aceyl es- duced body mass by 22% in the
obese male volunteer [4]. Firestonetrone,” says Firestone. He explains
that molecules like OE are signaling claims that in rat studies an approxi-
mately 15% body mass reduction ismolecules that can affect neurons in
the peripheral nervous system and routine. “And the weight they lose
consists of white adipose tissue, notthe CNS. “There is accumulating evi-
dence that OE is a blood-borne mol- bone or skeletal mass, not paren-
chymal organ mass, not extracellu-ecule that works to depress appetite
centrally,” he says. lar fluid,” he says.
“We don’t yet know a great dealOE is present in the plasma of
mammals—rodents and man—in about the natural biology of OE,
other than it exists in plasma in pro-the ng/ml level and exists in plasma
roughly in proportion to the amount portion to body mass and body fat
up to a certain point and then itsof body fat. “That relationship holds
until you get to a body mass index levels seem to be relatively low in
obese people,” says Firestone. He(BMI) of 30 or greater,” says Fire-
stone. “Once you get to the obesity also knows OE is synthesized in pe-
ripheral fat, released into blood, andlevel, the OE level remains flat. Obese
people have relatively less OE in their interacts with hypothalamic neu-
rons, all together something like ablood than their body mass and fat
content would predict.” peripheral lipid signaling molecule
For as yet unexplained reasons, that will stimulate the appetite con-
obese individuals appear to manu- trol center in the brain.
facture inadequate amounts of OE. Manhattan will file an IND for OE
“The conclusion we reach is that in late 2004, with human phase I clin-
perhaps OE is one of those coarse ical studies set to begin by 2005 in
controls on the storage of calories, the US.
like leptin—something manufac-
tured in fat that feeds back to the
Referencesbrain that says ‘I have sufficient fat
stores’,” explains Firestone. And the
1. Batterham, R.L., Cohen, M.A., Ellis, S.M.,hypothesis is that obese people syn-
Le Roux, C.W., Withers, D.J., Frost, G.S.,
thesize less OE per unit of body Ghatei, M.A., and Bloom, S.R. (2003). N.
weight than is needed. “Less of it Engl. J. Med. 349, 941–948.
2. Tschop, M., Castaneda, T.R., Joost, H.G.,circulates in blood, which probably
